Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

Key Takeaways Pfizer's oncology sales make up 25% of total revenues, boosted by its 2023 Seagen acquisition. Bristol Myers expands its oncology pipeline with Mirati and RayzeBio acquisitions and new drug approvals. PFE shows better stock performance and a 7.2% dividend yield, edging out BMY's 5.29% amid valuation parity.Pharma/biotech giants Pfizer (PFE) and Bristol Myers (BMY) boast of a dominant position in the lucrative oncology space.Oncology or cancer is one of the most sought-after areas in the phar ...